Diabetes Mellitus Clinical Trial
Official title:
Effects of Non-Surgical Periodontal Treatment on the Gingival Crevicular Fluid Levels of Vaspin and Omentin-1 in Type 2 Diabetic Patients With Chronic Periodontitis
The aim of the present study were 1) to determine the role of these adipokines in the pathogenesis of periodontal disease, inflammation and tissue destruction comparing with gingival crevicular fluid (GCF) levels of TNF-α, which has a known pro-inflammatory effect in periodontal disease, 2) to investigate the effect of non-surgical periodontal treatment on GCF vaspin and omentin levels in type 2 diabetic (T2DM) patients with Chronic Periodontitis (CP).
Adipose tissue produces and releases a variety of inflammatory factors, including
adipocytokines , such as adiponectin, leptin, tumor-necrosis factor alpha (TNF-α),
interleukin-6 (IL-6), visfatin, vaspin and omentin.These adipokines have widespread effects
on carbohydrate and lipid metabolism and appear to play an important role in the
pathogenesis of insulin resistance, diabetes, inflammation, wound healing, and immune
responses.Recently, studies evaluated the serum vaspin and omentin levels as inflammatory
markers in T2DM patients. Based on the above mentioned studies, the present investigation
has been devoted to elucidate the role of adipokines in the pathogenesis that might link DM
and periodontal disease. We hypothesize that vaspin and omentin are inflammatory adipokines
involved in chronic inflammation and are associated with T2DM and CP. Additionally, the
evaluation of GCF vaspin and omentin levels can provide advance the biologic link between DM
and periodontitis. Until now, levels of GCF vaspin and omentin in CP patients with T2DM
before and after non-surgical periodontal treatment has not been explored. Hence, the aim of
the present study were 1) to determine the role of these adipokines in the pathogenesis of
periodontal disease, inflammation and tissue destruction comparing with GCF levels of TNF-α,
which has a known pro-inflammatory effect in periodontal disease 2) to investigate the
effect of non-surgical periodontal treatment on GCF vaspin and omentin levels in T2DM
patients with CP.
A total of 15 T2DM patients with CP ( DM-CP group), 15 CP patients (CP group), 15 T2DM
patients (DM-CTRL group) and 15 subjects with systemically and periodontally healthy control
subjects (CTRL group) were included in the study. Diabetic subjects should have T2DM and had
no any known systemic diseases other than T2DM. The glycemic status of patients previously
diagnosed with T2DM was confirmed by their glycated haemoglobin (HbA1c) levels. Periodontal
disease status was determined according to clinical and radiographic criteria by the 1999
classification of periodontal disease.
Subjects were clinically evaluated using the following parameters; plaque index (PI),
gingival index (GI) , PD, clinical attachment level (CAL) and BOP (deemed positive if it
occurred within 15 seconds after probing). Clinical measurements were recorded by one
calibrated examiner at six sites per tooth from the full-mouth teeth excluding third molars
using with a Williams periodontal probe (Nordent Manufacturing Inc., ElkGrove Village, IL,
USA) calibrated in millimeters. Anthropometric measurements included weight (kg) and height
(m) of the subjects to calculate the BMI ( weight divided by the square of height, kg/m2 ).
All clinical and radiological examinations, sampling site selections were performed by one
examiner and the samples were collected on the day after clinical examination of patients.
This was to prevent contamination of GCF with blood associated with the probing of inflamed
sites. The deepest two pocket sites of single-rooted teeth were selected for the collection
of GCF in both periodontitis groups, and also two pocket sites with an absence of
inflammation were sampled to ensure the collection of an adequate amount of GCF in control
groups. In patients from CP and DM-CP groups, sites showing greatest PD when measured with a
periodontal probes and signs of inflammation, along with radiographic conformation of bone
loss were sampled. GCF samples were collected at baseline and after 8 weeks from baseline
sampling in both periodontitis groups, and only at baseline in control groups. To avoid
salivary contamination, the sites to be sampled were rinsed with water, isolated by cotton
rolls and gently air dried. Paper strips (Periopaper; Oraflow Inc.,Smithtown, NY, USA) were
gently inserted 1-2 mm into the sulcus/pocket for 30 seconds. Care was taken to avoid
mechanical injury of the gingival tissues. All samples containing blood and saliva were
discarded. The two strips from two sites of each individual were placed into coded sealed
plastic eppendorf tubes and pooled before freezing at -80 degree
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |